Study Comparing the Bowel Cleansing Efficacy of PLENVU® Versus SELG-ESSE® Using a 2-Day Split Dosing Regimen.

PHASE4CompletedINTERVENTIONAL
Enrollment

399

Participants

Timeline

Start Date

October 31, 2018

Primary Completion Date

March 31, 2020

Study Completion Date

March 31, 2020

Conditions
Colon PolypColon AdenomaColon Lesion
Interventions
DRUG

PEG3350

"PLENVU® supplied as two powder-for-oral-solution formulations. One formulation contains PEG3350, sodium sulphate and electrolytes, and the second formulation contains PEG3350, sodium ascorbate, ascorbic acid, and electrolytes.~PLENVU® Administration: 2-Day Split-Dosing Regimen (to commence in the evening of the day before colonoscopy)."

DRUG

Macrogol 4000

"SELG-ESSE® supplied as powder-for-oral-solution containing PEG4000, simethicone, sodium sulphate and sodium bicarbonate, and electrolytes.~SELG-ESSE® Administration: 2-Day Split-Dosing Regimen (to commence in the evening of the day before colonoscopy)."

Trial Locations (5)

20089

Humanitas Research Hospital, Rozzano

Unknown

Centro di Riferimento Oncologico, Aviano

Fondazione Poliambulanza, Brescia

Nuovo Regina Margherita Hospital, Roma

ISMETT, Palermo

All Listed Sponsors
lead

Istituto Clinico Humanitas

OTHER

NCT03742232 - Study Comparing the Bowel Cleansing Efficacy of PLENVU® Versus SELG-ESSE® Using a 2-Day Split Dosing Regimen. | Biotech Hunter | Biotech Hunter